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ABSTRACT
BACKGROUND The safety of nonsteroidal anti-inﬂammatory drug (NSAID) and aspirin coadministration is uncertain.
OBJECTIVES The aim of this study was to compare the safety of combining NSAIDs with low-dose aspirin.
METHODS This analysis of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus
Ibuprofen or Naproxen) trial included 23,953 patients with osteoarthritis or rheumatoid arthritis at increased cardio-
vascular risk randomized to celecoxib, ibuprofen, or naproxen. The on-treatment population was used for this study.
Outcomes included composite major adverse cardiovascular events, noncardiovascular death, gastrointestinal or renal
events, and components of the composite. Cox proportional hazards models compared outcomes among NSAIDs strat-
iﬁed by aspirin use following propensity score adjustment. Kaplan-Meier analysis was used to compare the cumulative
probability of events.
RESULTS When taken without aspirin, naproxen or ibuprofen had greater risk for the primary composite endpoint
compared with celecoxib (hazard ratio [HR]: 1.52; 95% conﬁdence interval [CI]: 1.22 to 1.90, p <0.001; and HR: 1.81;
95% CI: 1.46 to 2.26; p <0.001, respectively). Compared with celecoxib, ibuprofen had more major adverse cardio-
vascular events (p < 0.05), and both ibuprofen and naproxen had more gastrointestinal (p < 0.001) and renal (p < 0.05)
events. Taken with aspirin, ibuprofen had greater risk for the primary composite endpoint compared with celecoxib (HR:
1.27; 95% CI: 1.06 to 1.51; p < 0.01); this was not signiﬁcantly higher with naproxen (HR: 1.18; 95% CI: 0.98 to 1.41;
p ¼ 0.08). Among patients on aspirin, major adverse cardiovascular events were similar among NSAIDs, and compared
with celecoxib, ibuprofen had more gastrointestinal and renal events (p < 0.05), while naproxen had more gastroin-
testinal events (p < 0.05), without a difference in renal events. Similar results were seen on adjusted Kaplan-Meier
analysis.
CONCLUSIONS Celecoxib has a more favorable overall safety proﬁle than naproxen or ibuprofen when taken without
aspirin. Adding aspirin attenuates the safety advantage of celecoxib, although celecoxib is still associated with fewer
gastrointestinal events than ibuprofen or naproxen and fewer renal events than ibuprofen. (Prospective Randomized
Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen [PRECISION]; NCT00346216) (J Am Coll Cardiol
2018;71:1741–51) © 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
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C oncomitant use of nonsteroidalanti-inﬂammatory drugs (NSAIDs)and aspirin is widespread. In 2010,
>43 million U.S. adults were regular aspirin
users, and >28 million took NSAIDs regularly
(1,2). An estimated 20% to 50% of patients
with osteoarthritis or rheumatoid arthritis
take aspirin daily (3,4). The coadministration
of NSAIDs and aspirin has raised safety con-
cerns, because both inhibit synthesis of pros-
tanoids in tissues in which these lipid
mediators may have protective effects.
Furthermore, nonselective NSAIDs may
compete with aspirin for its binding site on
cyclooxygenase (COX)–1 (5,6), blocking aspi-
rin’s ability to acetylate a serine residue on
COX-1 necessary for platelet inhibition (6,7).
Observational studies and meta-analyses suggest
that both NSAIDs nonselective for COX-1 or COX-2
and NSAIDs selective for COX-2 have adverse ef-
fects, including cardiovascular, gastrointestinal (GI),
and renal events, compared with placebo (8–13).
Studies have reported conﬂicting results with regard
to whether adding aspirin to an NSAID modiﬁes these
risks (14–19). Likewise, there have been reports of
aspirin failure in patients with inﬂammatory disor-
ders, particularly among patients on NSAIDs (20). The
relative safety of combining aspirin and NSAIDs with
various degrees of COX-1 and COX-2 inhibition is not
well understood, presenting challenges to providing
patient recommendations on this subject.
Accordingly, we performed a propensity score–
adjusted substudy of the PRECISION (Prospective
Randomized Evaluation of Celecoxib Integrated
Safety Versus Ibuprofen or Naproxen) trial to evaluate
the safety of combining aspirin (a selective COX-1
inhibitor) with celecoxib (a selective COX-2 inhibi-
tor), naproxen (a nonselective COX-1 > COX-2 inhib-
itor), or ibuprofen (a nonselective COX-2 > COX-1
inhibitor).
METHODS
STUDY POPULATION. This was a post hoc analysis of
the PRECISION trial. The design, rationale, and pri-
mary results of PRECISION have been previously
published (3,21). Brieﬂy, PRECISION was a multi-
center, randomized controlled trial of patients with
osteoarthritis or rheumatoid arthritis on long-term
NSAIDs at increased cardiovascular risk that demon-
strated the noninferiority of moderate-dose celecoxib
(100 to 200 mg twice daily) to naproxen (375 to
500 mg twice daily) and ibuprofen (600 to 800 mg 3
times daily) with regard to cardiovascular safety. The
PRECISION trial protocol pre-speciﬁed an analysis
stratiﬁed by aspirin use a priori. However, the sta-
tistical methodology used to accomplish this was
established post hoc.
As previously reported, in PRECISION, patients
were randomized according to their primary diag-
nosis (osteoarthritis or rheumatoid arthritis), and
stratiﬁed by low-dose aspirin (#325 mg) use at base-
line to ensure equal distribution among NSAIDs. The
study protocol did not permit doses of aspirin
>325 mg. All subjects were provided with once-daily
esomeprazole 20 to 40 mg as a gastroprotective
agent regardless of aspirin use. All patients gave
informed consent before enrollment in the study.
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STUDY COMPARISONS. We analyzed outcomes in
PRECISION on the basis of the presence or absence of
aspirin use and the speciﬁc NSAID administered, in
the following comparisons: 1) aspirin versus no
aspirin use among all patients (i.e., all NSAIDs pooled
together); 2) aspirin versus no aspirin use among pa-
tients on celecoxib, naproxen, or ibuprofen (i.e.,
NSAIDs analyzed separately); 3) celecoxib, naproxen,
or ibuprofen use in patients not on aspirin; and 4)
celecoxib, naproxen, or ibuprofen use in patients on
aspirin.
STUDY ENDPOINTS AND FOLLOW-UP. The primary
endpoint for this analysis was the composite
endpoint of any safety event, deﬁned as the ﬁrst
occurrence of an extended major adverse cardiovas-
cular event (MACE), noncardiovascular death, clini-
cally signiﬁcant GI event, iron-deﬁciency anemia of
GI origin, or serious renal event. The deﬁnition of
extended MACE included death due to cardiovascular
causes (including hemorrhagic death), nonfatal
myocardial infarction, nonfatal stroke, coronary
revascularization, or hospitalization for unstable
angina or transient ischemic attack. Clinically signif-
icant GI events included acute gastric or intestinal
hemorrhage, symptomatic ulcer, gastric outlet
obstruction, and gastric or intestinal perforation.
A serious renal event was deﬁned as creatinine
$2.0 mg/dl and an increase of $0.7 mg/dl from
baseline serum creatinine, hospitalization for acute
renal failure, or initiation of hemodialysis.
Secondary endpoints were individual components
of the composite outcome, including extended MACE,
noncardiovascular death, and GI or renal events, as
well as MACE as deﬁned by the Antiplatelet Trialists’
Collaboration (APTC) criteria (death due to cardio-
vascular causes or hemorrhagic death, nonfatal
myocardial infarction, or nonfatal stroke) (22).
Outcomes were analyzed in the modiﬁed
intention-to-treat (the “on-treatment”) population of
patients conﬁrmed to be taking study drug during
follow-up. Patients were followed at regular intervals
via ofﬁce visits or telephone calls as speciﬁed in the
study protocol. The protocol pre-speciﬁed a mini-
mum follow-up duration of 18 months, with
censoring of data from event-free patients through
30 days after the last dose of the study medication up
to a maximum of 43 months.
STATISTICAL ANALYSIS. Baseline characteristics are
presented as mean  SD for continuous variables (as
all were conﬁrmed to be normally distributed) or
count (percentage of patients) for categorical vari-
ables. There was no collinearity among covariates.
For each endpoint, the raw number of events (per-
centage of total patients) over time is reported. Pa-
tient characteristics were stratiﬁed by the presence or
absence of aspirin use at randomization, pooled in all
patients (Table 1) as well as within each individual
NSAID group (celecoxib, naproxen, and ibuprofen)
(Online Table 1). Differences between aspirin and no-
aspirin groups were assessed using 2-tailed Student’s
t-tests or chi-square tests.
Approximately 1.5% of patients had 1 or more
missing values of baseline characteristics. To make
the best use of the data, all baseline data were made
complete by imputing missing values using multi-
variate imputation by chained equations, which was
implemented with the MI procedure in SAS (SAS
Institute, Cary, North Carolina). For each endpoint, 5
imputed datasets were generated. All analyses in this
study other than reported in Table 1 were performed
and reported on the datasets containing imputed
values but were repeated in the original nonimputed
datasets to ensure consistency in results. Results
TABLE 1 Patient Characteristics Stratiﬁed by
Aspirin Use at Randomization
No Aspirin
(n ¼ 12,935)
Aspirin
(n ¼ 11,018) p Value
Age, yrs 61.6  9.6 65.1  8.8 <0.001
Female 9,063 (70.1) 6,297 (57.2) <0.001
Race <0.001
White 9,082 (70.2) 8,801 (79.9)
Black 2,012 (15.6) 1,292 (11.7)
Asian 394 (3.0) 114 (1.0)
Unspeciﬁed/other 1,447 (11.2) 811 (7.4)
BMI, kg/m2 32.5  7.6 32.7  7.1 0.12
Arthritis diagnosis <0.001
OA 11,409 (88.2) 10,116 (91.8)
RA 1,523 (11.8) 902 (8.2)
Established CAD 1,133 (8.9) 3,072 (28.1) <0.001
Diabetes mellitus 4,138 (32.4) 4,308 (39.4) <0.001
Hypertension 9,718 (76.1) 8,928 (81.6) <0.001
Dyslipidemia 7,371 (57.7) 7,601 (69.5) <0.001
Current smoker 3,151 (24.4) 1,825 (16.6) <0.001
Current statin use 5,612 (43.4) 7,302 (66.3) <0.001
Current DMARD use 1,097 (8.5) 651 (5.9) <0.001
Systolic BP, mm Hg 125.3  10.5 125.2  10.5 0.44
Diastolic BP, mm Hg 76.1  7.8 74.6  8.1 <0.001
Creatinine, mg/dl 0.87  0.22 0.92  0.22 <0.001
C-reactive protein, mg/dl 3.0 (1.4–6.7) 2.4 (1.1–5.2) <0.001
HAQ disability index 1.13  0.61 1.08  0.61 <0.001
VAS score, mm 55.4  23.7 52.5  23.7 <0.001
Values are mean  SD, n (%), or median (interquartile range). Results are pooled
among all nonsteroidal anti-inﬂammatory drugs (celecoxib, naproxen, and
ibuprofen).
BMI ¼ body mass index; BP ¼ blood pressure; CAD ¼ coronary artery disease;
DMARD ¼ disease-modifying antirheumatic drug; HAQ ¼ Health Assessment
Questionnaire; OA ¼ osteoarthritis; RA ¼ rheumatoid arthritis; VAS ¼ visual
analogue scale.
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from the imputed and nonimputed datasets were
very similar.
To adjust for differences between patients taking
aspirin and not, propensity scores for aspirin treat-
ment and corresponding stabilized inverse probabil-
ity of treatment weights (IPTWs) were calculated
using a universal binary logistic regression model
including all of the baseline characteristics as cova-
riates (23), in each of the imputed datasets for each
endpoint. Improvement in the balance of baseline
characteristics was assessed by evaluating a plot of
the absolute standardized differences with and
without IPTW (Online Figure 1). An absolute value in
standardized differences of <10% for each variable
served to determine adequate covariate balance (24).
Cox proportional hazards analysis was performed
for each outcome using average treatment effect
weighting (25), given that the treatment effect of
aspirin was applied to all the study participants at
baseline. The proportional hazards assumption was
examined for aspirin in the overall patients and in
each NSAID treatment (in the form of dummy vari-
ables) using a plot of Schoenfeld residuals; no devi-
ation from the assumption was observed in any case.
Multivariate model selection was then conducted
through the stepwise selection method, incorporating
normalization of stabilized IPTWs. Demographic
characteristics (age, sex, race, and body mass index),
presence or absence of aspirin use, and NSAID treat-
ments were forced in, and interaction terms of cova-
riates with time to ﬁrst event were added to the
model. Those with p values <0.10 were retained at
each iteration. In each iteration, parameters in the
Cox model were estimated using a robust variance
estimator (26). The selected variables constituted the
covariate set in the ﬁnal Cox model, which used all
the aforementioned adjustment methods for a
multivariate setting. The Cox regression results from
the 5 imputed datasets were then combined and
reported in the form of hazard ratios (HRs) and
95% conﬁdence interval (CIs) using the MIANALYZE
procedure in SAS and were graphed in forest plots.
IPTW-adjusted Kaplan-Meier curves were also
created comparing outcomes among the NSAIDs in
each of the aspirin and no-aspirin groups separately.
Interaction testing for NSAID and aspirin use, as well
as coronary artery disease (CAD) and aspirin use, were
performed. A separate sensitivity analysis evaluated
outcomes on the basis of the presence or absence of
CAD given its possible collinearity and interaction
with aspirin use. Two-sided p values <0.05 were
considered to indicate statistical signiﬁcance. The
analyses were performed using SAS version 9.4. The
forest plots were drawn using the FORESTPLOT
package in R version 3.4.0 (R Foundation for Statis-
tical Computing, Vienna, Austria). The plot of abso-
lute standardized differences was made using
SigmaPlot version 11.0 (Systat, San Jose, California).
RESULTS
PATIENT CHARACTERISTICS. This study included
23,953 patients (24,222 patients were randomized in
PRECISION, but 141 patients were excluded because
of enrollment errors and 128 patients did not have
data on aspirin use); 8,030 were assigned to celecoxib,
7,933 to naproxen, and 7,990 to ibuprofen. Aspirin was
used by 11,018 patients (46.0%) at randomization;
3,683 (45.9%) were on both celecoxib plus aspirin,
3,640 (45.9%) naproxen plus aspirin, and 3,695
(46.2%) ibuprofen plus aspirin. Aspirin users were
older, more likely to be male, and more likely have a
history of CAD, diabetes mellitus, hypertension, dys-
lipidemia, and active statin use. There was a lower
prevalence of smoking among aspirin users compared
with nonusers (Table 1). The distribution of baseline
characteristics was similar when evaluating each
NSAID group separately (Online Table 1). The observed
differences in patient characteristics were success-
fully balanced after propensity score weighting
(Online Figure 1). Almost all patients were on proton
pump inhibitors at randomization (23,816 [99.4%]).
ADDITION OF ASPIRIN TO NSAID THERAPY. There
was no signiﬁcant difference in the composite safety
endpoint with the addition of aspirin when all NSAIDs
were pooled together (adjusted HR: 1.10; 95% CI: 0.97
to 1.25; p ¼ 0.13) (Online Figure 2). However, patients
taking celecoxib plus aspirin had a higher risk for the
composite safety endpoint compared with those on
celecoxib alone (2.0% vs. 1.0%; adjusted HR: 1.44;
95% CI: 1.13 to 1.82; p ¼ 0.003). This was driven by a
higher rate of extended MACE with celecoxib plus
aspirin compared with celecoxib alone (1.4% vs. 0.7%;
adjusted HR: 1.51; 95% CI: 1.14 to 2.01; p ¼ 0.004).
There was a marginally signiﬁcant interaction effect
between NSAID and aspirin use (p ¼ 0.046) on the
composite safety endpoint. There were otherwise no
differences in the composite safety endpoint or
extended MACE with the addition of aspirin to nap-
roxen or ibuprofen. Likewise, there were no differ-
ence in APTC-deﬁned MACE, GI events, or renal
events with the addition of aspirin for any of the
NSAIDs.
OUTCOMES OF CELECOXIB, NAPROXEN, AND
IBUPROFEN WITHOUT ASPIRIN. Among patients not
on aspirin, naproxen or ibuprofen each associated
with greater risk for the composite safety endpoint
compared with patients on celecoxib (4.5% vs. 3.0%
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and 5.0% vs. 3.0%, respectively; naproxen vs. cele-
coxib adjusted HR: 1.52; 95% CI: 1.22 to 1.90;
p < 0.001; ibuprofen vs. celecoxib HR: 1.81; 95% CI:
1.46 to 2.26; p < 0.001) (Figure 1). These results
derived primarily from a greater risk for GI events
with either naproxen compared with celecoxib
(1.3% vs. 0.5%; adjusted HR: 2.60; 95% CI: 1.59 to
4.27; p < 0.001) and ibuprofen compared with cele-
coxib (1.5% vs. 0.5%; adjusted HR: 3.20; 95% CI: 1.97
to 5.22; p < 0.001). However, when comparing
ibuprofen with celecoxib, there was also slightly
higher risk for extended MACE (adjusted HR: 1.35;
95% CI: 1.02 to 1.78; p ¼ 0.039) and APTC-deﬁned
MACE (adjusted HR: 1.47; 95% CI: 1.04 to 2.08;
p ¼ 0.031), and compared with celecoxib, naproxen
was associated with a greater risk for renal events
(adjusted HR: 2.09; 95% CI: 1.10 to 3.96; p ¼ 0.024),
while excess risk with ibuprofen was borderline sig-
niﬁcant (adjusted HR: 1.93; 95% CI: 1.00 to 3.73;
p ¼ 0.052).
On adjusted Kaplan-Meier analysis, the composite
safety endpoint and extended MACEs occurred least
frequently with celecoxib compared with naproxen or
ibuprofen (Central Illustration) (log-rank p < 0.0001
and p ¼ 0.0012, respectively). Similarly, GI events
(p < 0.0001) and renal events (p ¼ 0.0005) were least
common with celecoxib compared with the other
NSAIDs (Figures 2A and 2C).
OUTCOMES OF CELECOXIB, NAPROXEN, AND
IBUPROFEN COMBINED WITH ASPIRIN. Patients
taking ibuprofen plus aspirin had greater risk for the
composite safety endpoint compared with celecoxib
plus aspirin (7.1% vs. 6.0%; adjusted HR: 1.27; 95% CI:
1.06 to 1.51; p ¼ 0.01) (Figure 3). However, there was
no difference in extended MACE or APTC-deﬁned
MACE between NSAIDs with the addition of aspirin.
The difference in the composite safety endpoint was
driven by an increased risk for GI events with
ibuprofen plus aspirin compared with celecoxib plus
aspirin (1.4% vs. 0.9%; adjusted HR: 1.71; 95% CI: 1.10
to 2.67; p ¼ 0.017), which was also observed with
naproxen plus aspirin compared with celecoxib plus
aspirin (1.6% vs. 0.9%; adjusted HR: 1.91; 95% CI: 1.24
to 2.94; p ¼ 0.003). Likewise, the hazard of renal
events was greater with ibuprofen plus aspirin
compared with celecoxib plus aspirin (1.2% vs. 0.6%;
adjusted HR: 2.01; 95% CI: 1.23 to 3.30; p ¼ 0.005), but
there was no difference with naproxen plus aspirin
compared with celecoxib plus aspirin. Event rates
tended to be higher for all endpoints with aspirin
addition, regardless of which NSAID was used
(Figures 1 and 3).
FIGURE 1 Outcomes in Non–Aspirin Users on Naproxen or Ibuprofen Compared With Celecoxib
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The number of events (percentage of total) is reported. APTC ¼ Antiplatelet Trialists’ Collaboration; CI ¼ conﬁdence interval;
GI ¼ gastrointestinal; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular event.
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Furthermore, adjusted Kaplan-Meier analysis
demonstrated that the addition of aspirin attenuated
the beneﬁt of celecoxib compared with naproxen and
ibuprofen with regard to the composite safety
endpoint and extended MACE (Central Illustration).
Likewise, in the presence of aspirin, there was less
differentiation in renal events among NSAIDs
(Figure 2D). However, GI events remained least
frequent with celecoxib (log-rank p ¼ 0.004)
(Figure 2B).
CAD AND ASPIRIN COMPLIANCE SENSITIVITY ANALYSES.
In a pre-speciﬁed sensitivity analysis, comparing pa-
tients with CAD with those without, the relative
hazard of the composite safety endpoint was
approximately the same whether aspirin was also
used (adjusted HR: 2.23; 95% CI: 1.90 to 2.60;
p < 0.001) or aspirin was not used (adjusted HR: 2.01;
95% CI: 1.56 to 2.59; p < 0.001), demonstrating no
signiﬁcant interaction between CAD and aspirin use
(Online Figure 3) (interaction p ¼ 0.35).
CENTRAL ILLUSTRATION Safety of Combined Aspirin and Nonsteroidal Anti-Inﬂammatory Drug Use
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Adjusted Kaplan-Meier curves for the composite safety endpoint and extended major adverse cardiovascular event (MACE), stratiﬁed by aspirin use. Among patients
not on aspirin, celecoxib had the lowest incidence of composite safety events and extended MACE. The addition of aspirin attenuated the relative safety beneﬁt of
celecoxib.
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Only 304 patients (1.3%) discontinued aspirin after
randomization, and 964 patients (4.0%) who were not
on aspirin started aspirin during the study (this was
equally distributed among the NSAIDs). When
excluding these patients, the results for the primary
endpoint were not signiﬁcantly different.
DISCUSSION
This study demonstrates that the relative cardio-
vascular and overall safety of NSAID therapy is
modiﬁed by concomitant aspirin use. Speciﬁcally,
celecoxib was associated with a more favorable
overall safety proﬁle than naproxen or ibuprofen
among regular NSAID users not taking aspirin.
However, the addition of aspirin attenuated the
relatively favorable safety proﬁle of celecoxib, and
although there was still a slight advantage of cele-
coxib over ibuprofen with regard to composite
safety events, there were no longer differences in
extended MACE or APTC-deﬁned MACE. However,
celecoxib was still associated with fewer GI events
FIGURE 2 Adjusted Kaplan-Meier Curves for the Cumulative Incidence of Gastrointestinal and Renal Events, Stratiﬁed by Aspirin Use
1.00
A
0.99
0.98
0.97
0.96
0.95
0 250 500 750 1000 1250
4410 3075 2336 1794 1299 997
4283 2830 2081 1573 1187 906
4312
Celecoxib
Ibuprofen
Naproxen 2972 2208 1681 1279 971
Time to Event (Days)
No Aspirin
Ev
en
t-
Fr
ee
 S
ur
vi
va
l
GI Events
Renal
Events
Log rank p < 0.0001
1.00
C
0.99
0.98
0.97
0 250 500 750 1000 1250
4410 3077 2345 1799 1302 1000
4283 2830 2087 1586 1195 907
4312
Celecoxib
Ibuprofen
Naproxen 2933 2212 1685 1282 974
Time to Event (Days)
Ev
en
t-
Fr
ee
 S
ur
vi
va
l
Log rank p = 0.0005
1.00
B
0.99
0.98
0.97
0.96
0.95
0 250 500 750 1000 1250
3670 2561 1993 1529 1139 872
3674 2492 1853 1406 1049 795
3623
Celecoxib
Ibuprofen
Naproxen 2542 1956 1453 1059 819
Time to Event (Days)
Aspirin
Ev
en
t-
Fr
ee
 S
ur
vi
va
l
Log rank p = 0.0040
1.00
D
0.99
0.98
0.97
0 250 500 750 1000 1250
3670 2561 1993 1528 1142 875
3674 2491 1858 1410 1057 804
3623
Celecoxib
Ibuprofen
Naproxen 2547 1963 1463 1065 826
Time to Event (Days)
Ev
en
t-
Fr
ee
 S
ur
vi
va
l
Log rank p = 0.0546
Celecoxib Naproxen Ibuprofen
The addition of aspirin attenuated the gastrointestinal (GI) and renal safety of celecoxib, although GI events were still less frequent with celecoxib than ibuprofen
or naproxen.
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than ibuprofen or naproxen and fewer renal events
than ibuprofen.
The primary ﬁndings of PRECISION were reported
in the intention-to-treat population, in which pa-
tients were grouped on the basis of the study drug to
which they were assigned at randomization. In that
analysis, events were counted regardless of whether
the study drug was stopped during the study. How-
ever, in studies of drug safety, the on-treatment
population can be more informative, as it considers
events only while patients are actually taking the
drug, and patients are censored a period of time after
the study drug is stopped (30 days in the present
analysis). This consideration has particular relevance
to studies of patients with pain, as these patients
discontinue medications frequently in favor of trying
other analgesic drugs. In this case, the intention-to-
treat analysis actually reﬂects the effects of these
other medications, while effects of the study drug are
better reﬂected in an on-treatment analysis. Indeed,
in PRECISION, study drug discontinuation was more
common than expected, as previously reported (see
PRECISION Trial Supplemental Appendix Figure S2)
(3). Furthermore, although the main ﬁndings of
PRECISION did contain a subgroup analysis stratiﬁed
by aspirin use, that analysis was in the intention-to-
treat population. The present study was better
equipped to assess the effect of aspirin on outcomes,
as it was a propensity score–adjusted analysis of
overall harms in the on-treatment population and
thus more relevant for the reasons described.
Our ﬁndings do not support the premise that se-
lective COX-2 inhibitors as a class increase cardio-
vascular risk compared with nonselective COX-1 and
COX-2 inhibitors (27). On the contrary, in the pri-
mary results from the PRECISION trial, selective COX-2
inhibition with celecoxib was noninferior for
cardiovascular safety to nonselective COX-2 > COX-1
inhibition with ibuprofen or COX-1 > COX-2 inhibi-
tion with naproxen in the intention-to-treat popula-
tion. The present analysis of the on-treatment
population is clinically more relevant with regard to
safety endpoints and showed the most favorable car-
diovascular safety proﬁle in patients with the selective
COX-2 inhibitor celecoxib alone. Adding COX-1 inhi-
bition with aspirin attenuated the cardiovascular
safety advantage of celecoxib and rendered the rela-
tive cardiovascular safety proﬁles of the NSAIDs
approximately equivalent. These ﬁndings support the
hypothesis and main ﬁndings of the PRECISION trial
FIGURE 3 Outcomes in Patients on Naproxen or Ibuprofen Compared With Celecoxib, With Combined Aspirin
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that the increased cardiovascular risk observed with
rofecoxib is not a COX-2 inhibition class effect.
Furthermore, our results suggest that celecoxib has a
more favorable cardiovascular safety proﬁle than
ibuprofen or naproxen among patients not on aspirin
and that the cardiovascular safety proﬁle of celecoxib
is noninferior to ibuprofen or naproxen among aspirin
users.
Our ﬁndings underscore the importance of appro-
priate patient counseling on the relative safety proﬁle
of NSAIDs when initiating therapy. Although short-
term NSAID use is likely safe (28), long-term use of
any NSAID has been associated with increased car-
diovascular, GI, and renal risk compared with placebo
in observational studies (9,29,30). However, if an
NSAID is required, the relative safety of the various
NSAIDs appears to be modiﬁed by concomitant
aspirin use. Physicians administering any NSAID
should consider the potential GI and renal hazards of
using combined NSAID and aspirin therapy. It would
be reasonable to consider gastric protection with an
H2 blocker or proton pump inhibitor if aspirin is also
used (29).
Most studies on the comparative safety of NSAIDs
have not investigated a possible interaction between
aspirin and NSAID use and have revealed conﬂicting
results, likely because of their heterogeneous study
designs and potential selection bias (16,17,31). A key
meta-analysis of 39 trials including more than 41,000
patients prior to PRECISION suggested that the inci-
dence of APTC-deﬁned MACE did not differ in pa-
tients treated with celecoxib compared with
nonselective NSAIDs regardless of aspirin use. How-
ever, this analysis did ﬁnd a lower cardiovascular
death rate with celecoxib compared with nonselective
NSAIDs (relative risk: 0.43; 95% CI: 0.19 to 0.95;
p ¼ 0.04) (14). Other observational studies have
revealed increased cardiovascular risk with ibuprofen
plus aspirin compared with ibuprofen alone (15,16),
while others have shown reduced risk (18) or no
change at all (17,32). Our study aimed to illuminate
these differences. Results of our study support the
relative safety of celecoxib compared with naproxen
or ibuprofen with regard to cardiovascular, GI, and
renal events.
The present study is a post hoc analysis of a ran-
domized controlled trial, and as such there were dif-
ferences in patient characteristics when stratiﬁed by
aspirin use (Table 1). This is a common issue seen in
most other observational studies of NSAID and aspirin
use and introduces bias that can be addressed only by
a properly designed trial. A strength of the present
study is the use of propensity score weighting to
adjust for baseline characteristics (Online Figure 1).
Our use of this technique allowed adjustment for
baseline characteristics, creating a “pseudo-random-
ization” result, increasing the validity to our results.
To the best of our knowledge, ours is the only study
on this topic to use such a technique. We further
incorporated multivariate adjustment into propensity
score–weighted survival regression analysis, a so-
called doubly robust adjustment, to reduce residual
confounding as much as possible (33).
STUDY LIMITATIONS. The strengths and limitations
of the PRECISION trial have been previously dis-
cussed (3). Although the analysis was pre-speciﬁed in
the trial protocol, the study was not designed to
detect an interaction between the study NSAIDs and
aspirin. Accordingly, the present analysis should be
considered hypothesis generating and needs to be
conﬁrmed by other studies. There were no compari-
sons of ibuprofen and naproxen in this study, though
the relative safety of these agents to each other can be
inferred via the Kaplan-Meier curves. In the present
study we did not evaluate outcomes stratiﬁed by
NSAID dose, given power limitations. Furthermore,
the NSAID doses in our study were moderate, in
accordance with approved labeling in the countries
where the trial was conducted. In addition, data on
erythrocyte sedimentation rate was not collected, and
although baseline levels of C-reactive protein were
reported, this variable was included post hoc and not
adjusted for. The present study was not designed to
evaluate outcomes on the basis of arthritis type
(osteoarthritis or rheumatoid arthritis), though a
separate analysis of PRECISION was recently pub-
lished addressing this (34).
CONCLUSIONS
Among patients not taking aspirin, moderate-dose
celecoxib is associated with a more favorable overall
safety proﬁle compared with naproxen or ibuprofen.
Combination with aspirin attenuates the safety
advantage of celecoxib, although celecoxib is
still associated with fewer GI events than ibuprofen
or naproxen and fewer renal events than ibuprofen.
These results suggest that in many cases, celecoxib
would be preferred to naproxen or ibuprofen,
especially if the patient is not required to take
aspirin.
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